{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer&page=8", "query": { "condition": "Non-Small Cell Lung Cancer", "page": 8 }, "page_size": 10 }, "pagination": { "page": 8, "page_size": 10, "total_count": 3687, "total_pages": 369, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer&page=9&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Non-Small+Cell+Lung+Cancer&page=7&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-24T01:01:16.637Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02898116", "title": "Phase 1/2 Study of Ensartinib and Durvalumab, in ALK-rearranged Non-small Cell Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer", "Carcinoma", "NSCLC" ], "interventions": [ { "name": "Ensartinib", "type": "DRUG" }, { "name": "Durvalumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ludwig Institute for Cancer Research", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 2, "start_date": "2017-05-10", "completion_date": "2017-08-04", "has_results": true, "last_update_posted_date": "2022-10-10", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT02898116" }, { "nct_id": "NCT02711137", "title": "Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumors" ], "interventions": [ { "name": "INCB057643", "type": "DRUG" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Paclitaxel", "type": "DRUG" }, { "name": "Rucaparib", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Ruxolitinib", "type": "DRUG" }, { "name": "Azacitidine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 137, "start_date": "2016-05-18", "completion_date": "2019-02-13", "has_results": true, "last_update_posted_date": "2025-10-21", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 16, "location_summary": "Birmingham, Alabama • La Jolla, California • Denver, Colorado + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02711137" }, { "nct_id": "NCT04285671", "title": "Necitumumab and Trastuzumab in Combination With Osimertinib for the Treatment of Refractory Epidermal Growth Factor Receptor (EGFR)-Mutated Stage IV Non-small Cell Lung Cancer", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Lung Non-Small Cell Carcinoma", "Refractory Lung Non-Small Cell Carcinoma", "Stage IV Lung Cancer American Joint Committee on Cancer (AJCC) v8", "Stage IVA Lung Cancer AJCC v8", "Stage IVB Lung Cancer AJCC v8" ], "interventions": [ { "name": "Necitumumab", "type": "BIOLOGICAL" }, { "name": "Osimertinib", "type": "DRUG" }, { "name": "Quality-of-Life Assessment", "type": "OTHER" }, { "name": "Questionnaire Administration", "type": "OTHER" }, { "name": "Trastuzumab", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL", "DRUG", "OTHER" ], "sponsor": "Jonsson Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 30, "start_date": "2021-01-29", "completion_date": "2027-12-02", "has_results": false, "last_update_posted_date": "2026-07-17", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 1, "location_summary": "Los Angeles, California", "locations": [ { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04285671" }, { "nct_id": "NCT05519293", "title": "Phase I/IIa Study of H002 in NSCLC With Active EGFR Mutation", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "H002", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "RedCloud Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 76, "start_date": "2022-12-15", "completion_date": "2025-02-28", "has_results": false, "last_update_posted_date": "2024-04-11", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 4, "location_summary": "Los Angeles, California • Boston, Massachusetts • New York, New York + 1 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Fairfax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05519293" }, { "nct_id": "NCT05304793", "title": "Testing a Cognitive Behavioral Model for Reducing Dyspnea in Patients With Lung Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Lung Non-Small Cell Carcinoma", "Lung Small Cell Carcinoma" ], "interventions": [ { "name": "Best Practice", "type": "OTHER" }, { "name": "Cognitive Behavior Therapy", "type": "BEHAVIORAL" }, { "name": "Questionnaire Administration", "type": "OTHER" } ], "intervention_types": [ "OTHER", "BEHAVIORAL" ], "sponsor": "Ohio State University Comprehensive Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2020-07-01", "completion_date": "2021-07-16", "has_results": false, "last_update_posted_date": "2024-10-31", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 1, "location_summary": "Columbus, Ohio", "locations": [ { "city": "Columbus", "state": "Ohio" } ], "official_url": "https://clinicaltrials.gov/study/NCT05304793" }, { "nct_id": "NCT04566393", "title": "Expanded Access to Ulixertinib (BVD-523) in Patients With Advanced MAPK Pathway-Altered Malignancies", "overall_status": "AVAILABLE", "study_type": "EXPANDED_ACCESS", "phases": [], "conditions": [ "Pancreatic Cancer", "Small Bowel Cancer", "Colorectal Cancer", "Melanoma", "Non Small Cell Lung Cancer", "Thyroid Cancer", "Bladder Cancer", "Head and Neck Cancer", "Gastric Cancer", "Esophageal Cancer", "Cholangiocarcinoma", "Ovarian Cancer", "Hepatocellular Carcinoma", "Glioblastoma", "MAPK Gene Mutation", "KRAS Activating Mutation", "BRAF Gene Mutation", "NRAS Gene Mutation", "HRAS Gene Mutation", "MEK Mutation", "ERK Mutation" ], "interventions": [ { "name": "Ulixertinib (BVD-523)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "xCures", "sponsor_class": "INDUSTRY", "healthy_volunteers": null, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": null, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2026-06-04", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 26, "location_summary": "Mobile, Alabama • Arroyo Grande, California • Newport Beach, California + 19 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Arroyo Grande", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT04566393" }, { "nct_id": "NCT00006212", "title": "Phosphorus-32 Plus Radiation Therapy and Chemotherapy in Treating Patients With Stage II or Stage III Non-small Cell Lung Cancer", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "vinblastine sulfate", "type": "DRUG" }, { "name": "phosphorus P32", "type": "RADIATION" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Center for Molecular Medicine", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1999-11", "completion_date": null, "has_results": false, "last_update_posted_date": "2013-09-17", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 1, "location_summary": "Garden City, New York", "locations": [ { "city": "Garden City", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00006212" }, { "nct_id": "NCT00787267", "title": "Phase II Study of Dasatinib in Previously Treated Patients With Advanced NSCLC", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer" ], "interventions": [ { "name": "Dasatinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Duke University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2008-09", "completion_date": "2013-06", "has_results": true, "last_update_posted_date": "2016-06-30", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 3, "location_summary": "Durham, North Carolina • Raleigh, North Carolina", "locations": [ { "city": "Durham", "state": "North Carolina" }, { "city": "Durham", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00787267" }, { "nct_id": "NCT00260598", "title": "LIFE-Lung Bronchoscopy in Patients at Risk for Developing Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Non-Small-Cell Lung Carcinoma", "Head and Neck Squamous Cell Cancer", "Pulmonary Disease, Chronic Obstructive" ], "interventions": [ { "name": "LIFE Bronchoscopy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "University of Pittsburgh", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "85 Years", "sex": "ALL", "summary": "18 Years to 85 Years" }, "enrollment_count": 142, "start_date": "1998-08", "completion_date": "2017-03", "has_results": false, "last_update_posted_date": "2018-09-13", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00260598" }, { "nct_id": "NCT07155187", "title": "A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan, Monotherapy or in Combination With Osimertinib, Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Non-Small Cell Lung Cancer", "c-MET" ], "interventions": [ { "name": "Telisotuzumab Adizutecan", "type": "DRUG" }, { "name": "Standard of Care", "type": "DRUG" }, { "name": "Osimertinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "AbbVie", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 490, "start_date": "2025-12-10", "completion_date": "2030-09", "has_results": false, "last_update_posted_date": "2026-10-05", "last_synced_at": "2026-10-24T01:01:16.637Z", "location_count": 16, "location_summary": "Springdale, Arkansas • Duarte, California • Irvine, California + 13 more", "locations": [ { "city": "Springdale", "state": "Arkansas" }, { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07155187" } ] }